Clinical Trial

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(PTS) in combination with or without first-line chemoimmunization based on standard treatment for stage IV driver gene-negative non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-19.
Trial Details
NCT Number NCT06607796
Lead Sponsor Zhou Chengzhi
Conditions Lung Cancer
Enrollment 180 participants
Start Date 2024-03-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-25